|Referral date||01 November 2011|
Scoped as part of Batch 20
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|21 March 2012||
The Institute has now been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for lapatinib in combination with paclitaxel, which was based on the results of the EGF104535 study.
Therefore, NICE has decided to suspend this appraisal on its current work programme.
For further information on our processes and methods, please see our CHTE processes and methods manual